Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Verastem ( (VSTM) ) has provided an update.
Verastem has secured a $150 million credit facility and $7.5 million equity investment from Oberland Capital, along with a strategic partnership with IQVIA, to support the launch of their investigational drug combination avutometinib and defactinib for recurrent KRAS mutant low-grade serous ovarian cancer. The collaboration aims to leverage IQVIA’s commercialization solutions, enhancing Verastem’s financial strength ahead of the potential FDA approval, which could significantly impact their market presence and provide new treatment options for complex cancer cases.
More about Verastem
Verastem Oncology is a late-stage development biopharmaceutical company focused on the development and commercialization of new medicines targeting RAS/MAPK pathway-driven cancers. The company’s pipeline includes novel small molecule drugs that inhibit RAF/MEK and FAK pathways, crucial to cancer cell survival and tumor growth.
YTD Price Performance: -11.71%
Average Trading Volume: 1,576,940
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $255M
For a thorough assessment of VSTM stock, go to TipRanks’ Stock Analysis page.
